15.76
0.26 (1.68%)
Previous Close | 15.50 |
Open | 15.53 |
Volume | 506,667 |
Avg. Volume (3M) | 616,350 |
Market Cap | 951,172,736 |
Price / Sales | 650.22 |
Price / Book | 2.86 |
52 Weeks Range | |
Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
Diluted EPS (TTM) | -3.06 |
Total Debt/Equity (MRQ) | 0.06% |
Current Ratio (MRQ) | 8.06 |
Operating Cash Flow (TTM) | -169.86 M |
Levered Free Cash Flow (TTM) | -68.57 M |
Return on Assets (TTM) | -25.34% |
Return on Equity (TTM) | -65.82% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Spyre Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 2.5 |
Technical Oscillators | -4.0 |
Average | 0.13 |
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 8.71% |
% Held by Institutions | 106.07% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |